http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106999431-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-141 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate | 2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106999431-B |
| titleOfInvention | anticancer composition |
| abstract | The present invention relates to a pharmaceutical formulation ARN-509 which can be administered to mammals, in particular humans, suffering from androgen receptor (AR) related diseases or disorders, in particular cancer, more specifically Is prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, chemotherapy-naive metastatic castration-resistant prostate cancer, biochemically recurrent hormone-sensitive prostate cancer, or high-risk non-metastatic Castration-resistant prostate cancer. In one aspect, the formulations comprise solid dispersions of ARN-509 and HPMCAS. In one aspect, a solid dispersion of ARN-509 and HPMCAS can be obtained, in particular by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture . In one aspect, a solid dispersion of ARN-509 and HPMCAS can be obtained by spray drying a mixture comprising ARN-509 and HPMCAS dissolved in a suitable solvent. |
| priorityDate | 2014-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.